Andrew M Scharenberg
Overview
Explore the profile of Andrew M Scharenberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
4411
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nicolai C, Parker M, Qin J, Tang W, Ulrich-Lewis J, Gottschalk R, et al.
Blood
. 2024 Jun;
144(9):977-987.
PMID: 38861668
Chimeric antigen receptor (CAR) T-cell therapies have demonstrated transformative efficacy in treating B-cell malignancies. However, high costs and manufacturing complexities hinder their widespread use. To overcome these hurdles, we have...
2.
Schmidt M, Gupta A, Bednarski C, Gehrig-Giannini S, Richter F, Pitzler C, et al.
Nat Commun
. 2023 Jun;
14(1):3503.
PMID: 37311765
No abstract available.
3.
Cook P, Yang S, Uenishi G, Grimm A, West S, Wang L, et al.
Mol Ther
. 2023 May;
31(8):2472-2488.
PMID: 37147803
Engineered T cells represent an emerging therapeutic modality. However, complex engineering strategies can present a challenge for enriching and expanding therapeutic cells at clinical scale. In addition, lack of in ...
4.
Michels K, Sheih A, Hernandez S, Brandes A, Parrilla D, Irwin B, et al.
J Immunother Cancer
. 2023 Mar;
11(3).
PMID: 36918221
Background: Chimeric antigen receptor (CAR) T-cell therapies have demonstrated transformational outcomes in the treatment of B-cell malignancies, but their widespread use is hindered by technical and logistical challenges associated with...
5.
Schmidt M, Gupta A, Bednarski C, Gehrig-Giannini S, Richter F, Pitzler C, et al.
Nat Commun
. 2021 Jul;
12(1):4219.
PMID: 34244505
Streptococcus pyogenes (Spy) Cas9 has potential as a component of gene therapeutics for incurable diseases. One of its limitations is its large size, which impedes its formulation and delivery in...
6.
Honaker Y, Hubbard N, Xiang Y, Fisher L, Hagin D, Sommer K, et al.
Sci Transl Med
. 2020 Jun;
12(546).
PMID: 32493794
Thymic regulatory T cells (tT) are potent inhibitors of autoreactive immune responses, and loss of tT function results in fatal autoimmune disease. Defects in tT number or function are also...
7.
Humbert O, Radtke S, Samuelson C, Carrillo R, Perez A, Reddy S, et al.
Sci Transl Med
. 2019 Aug;
11(503).
PMID: 31366580
Reactivation of fetal hemoglobin (HbF) is being pursued as a treatment strategy for hemoglobinopathies. Here, we evaluated the therapeutic potential of hematopoietic stem and progenitor cells (HSPCs) edited with the...
8.
Pattabhi S, Lotti S, Berger M, Singh S, Lux C, Jacoby K, et al.
Mol Ther Nucleic Acids
. 2019 Jul;
17:277-288.
PMID: 31279229
Gene editing following designer nuclease cleavage in the presence of a DNA donor template can revert mutations in disease-causing genes. For optimal benefit, reversion of the point mutation in HBB...
9.
Humbert O, Chan F, Rajawat Y, Torgerson T, Burtner C, Hubbard N, et al.
Blood Adv
. 2018 May;
2(9):987-999.
PMID: 29720491
Hematopoietic stem-cell gene therapy is a promising treatment of X-linked severe combined immunodeficiency disease (SCID-X1), but currently, it requires recipient conditioning, extensive cell manipulation, and sophisticated facilities. With these limitations...
10.
Paddock M, Buelow B, Takeda S, Scharenberg A
PLoS Biol
. 2018 Mar;
16(3):e1002621.
PMID: 29494577
[This corrects the article DOI: 10.1371/journal.pbio.1000428.].